← Back to Clinical Trials
Recruiting NCT04661072

NCT04661072 Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04661072
Status Recruiting
Phase
Sponsor Yale University
Condition Congenital Uterine Anomaly
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2021-07-14
Primary Completion 2027-08-01

Eligibility & Interventions

Sex Female only
Min Age 13 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2021-07-14 with a primary completion date of 2027-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.

Eligibility Criteria

Inclusion Criteria: * females * age: 13 or older * encounters limited to: Yale New Haven Hospital, Bridgeport Hospital, Greenwich Hospital and Lawrence+ Memorial Hospital. * diagnosis of any variation of CUA Exclusion Criteria: * who will decline to participate in a study upon contact * non-English speaking except Spanish speaking * unable to participate in consent or assent process due to mental disability

Contact & Investigator

Central Contact

Alla Vash-Margita, MD

✉ alla.vash-margita@yale.edu

📞 203-785-4010

Principal Investigator

Alla Vash-Margita, MD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT04661072 clinical trial?

This trial is open to female participants only, aged 13 Years or older, studying Congenital Uterine Anomaly. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04661072 currently recruiting?

Yes, NCT04661072 is actively recruiting participants. Contact the research team at alla.vash-margita@yale.edu for enrollment information.

Where is the NCT04661072 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT04661072 clinical trial?

NCT04661072 is sponsored by Yale University. The principal investigator is Alla Vash-Margita, MD at Yale University. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology